News & Updates

How does finerenone fare among DKD patients in real life?
How does finerenone fare among DKD patients in real life?
19 Jun 2025 byStephen Padilla

In patients with chronic kidney disease and type 2 diabetes who have not been previously treated with any mineralocorticoid receptor antagonist (MRA), the use of finerenone results in marked reductions in albuminuria, reports a study presented at ERA 2025.

How does finerenone fare among DKD patients in real life?
19 Jun 2025
First-line methotrexate on par with prednisone for sarcoidosis
First-line methotrexate on par with prednisone for sarcoidosis
18 Jun 2025 byStephen Padilla

The use of methotrexate as a first line of treatment for patients with pulmonary sarcoidosis delivers similar efficacy to prednisone as measured by forced vital capacity after 24 weeks, results of the PREDMETH trial have shown.

First-line methotrexate on par with prednisone for sarcoidosis
18 Jun 2025